Lilly Is Growing Its Next Crop Of Blockbusters

The pharma is digging deeper with early- and mid-stage R&D in age-related neurodegeneration, diabetes/obesity and other priority areas.

Indianapolis - Circa April 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals IV - Image
Lilly's R&D efforts focus on four key therapeutic areas

Eli Lilly and Company is counting on five key near-term approvals for organic growth, and offered investors a deep dive into those programs during a 15 December financial guidance and R&D overview, as well as highlighting how its focus on certain core disease areas is resulting in a robust mid- and early-stage pipeline.

Guggenheim Securities analyst Seamus Fernandez deemed it “a surprisingly broad and robust mid-stage pipeline” in a 16 December note, while Mizuho Securities analyst Vamil Divan highlighted “the progress Lilly continues...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By 

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

More from Business

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.